Advertisement
Clinical Therapeutics
Advanced searchSave search
Research Article| Volume 31, ISSUE 9, P2002-2011, September 2009

A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions

DOI:https://doi.org/10.1016/j.clinthera.2009.09.016
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions
Previous ArticleResults of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions
Next ArticleHealth care reform: Is the process the outcome?
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background: Valproic acid has been associated with a highly variable intersubject absorptive phase; therefore, magnesium salt (magnesium valproate [MgV]) was developed to diminish variation during enteric absorption.
      Objectives: The aims of this study were to assess the pharmacokinetics of single oral doses of MgV 500-mg solution, suspension, and enteric-coated tablets in a healthy Mexican population, and to compare formulation-related differences.
      Methods: This was a randomized, single-dose, 3-period, 6-sequence crossover study in healthy Mexican volunteers aged 18 to 45 years. In each period, subjects received single oral doses of 500-mg MgV solution, suspension, and enteric-coated tablet formulations, with a 7-day washout period between each dosing period. Serial blood samples were collected at 0 hour (prior to MgV administration) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 9, 12, 24, 48, and 72 hours after dosing. Valproate was measured by a new method of ultraperformance liquid chromatography coupled with mass spectrometry. Pharmacokinetic parameters of interest were Cmax, Tmax, AUC0–72, AUC0−∞, t½, Vd/F, CL/F, and mean residence time (MRT). Formulation-related differences were assayed in accordance with the Mexican regulatory bioequivalence criteria. Log-transformed values of Cmax and AUC were used to construct a classic 90% CI. Bioequivalence was established if the 90% CI for the mean test:reference ratio of log-transformed Cmax and AUC were within the range of 0.80 to 1.25. Tolerability was assessed based on subject interview, vital sign monitoring, and clinical assessment.
      Results: A total of 24 healthy volunteers (12 women and 12 men; mean [SD] age, 28.79 [6.5] years; height, 164 [9.8] cm; weight, 65.42 [8.95] kg; and body mass index, 24.28 [2.11] kg/m2) were included. For the MgV solution, the mean (SD) pharmacokinetic parameters of Cmax, Tmax, AUC0–72, AUC0–∞, t½, Vd/F, CL/F, and MRT were 59.75 (8.24) μg/mL, 0.542 (0.14) hours, 1099.67 (241.70) μg · h/mL, 1156.30 (264.01) μg · h/mL, 16.19 (2.36) hours, 9633.68 (1892.70) mL, 418.35 (92.01) mL/h, and 18.36 (1.44) hours, respectively. For the MgV suspension, the mean (SD) pharmacokinetic parameters of Cmax, Tmax, AUC0–72, AUC0−∞, t½, Vd/F, CL/F, and MRT were 55.04 (7.72) μg/mL, 0.773 (0.51) hour, 1057.76 (223.37) μg · h/mL, 1111.09 (245.07) μg · h/mL, 16.32 (2.20) hours, 1069.05 (1775.64) mL, 435.43 (99.59) mL/h,\ and 18.41 (1.43) hours, respectively. For the MgV entericcoated tablets, the mean (SD) pharmacokinetic parameters of Cmax, Tmax, AUC0–72, AUC0−∞, t½, Vd/F, CL/F, and MRT were 54.88 (6.73) μg/mL, 2.79 (0.89) hours, 1100.79 (216.70) μg · h/mL, 1163.61 (238.36) μg · h/mL, 16.48 (2.10) hours, 9675.15 (1659.36) mL, 412.36 (85.24) mL/h, and 19.95 (1.53) hours, respectively. The 90% CIs for the tablets:solution ratio were 82.15 to 95.44, 94.60 to 105.39, and 95.43 to 105.95 for Cmax, AUC0–72, and AUC0−∞, respectively. The 90% CIs for the suspension:solution ratio were 84.79 to 98.50, 88.89 to 99.02, and 89.15 to 98.97, respectively. The 90% CIs for the tablets:suspension ratio were 89.90 to 104.43, 100.84 to 112.34, and 101.60 to 112.80, respectively.
      Conclusion: This single-dose study found that the 3 formulations (solution, suspension, and enteric-coated tablets) of MgV met the regulatory criteria for bioequivalence in these healthy, fasting, Mexican volunteers.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Food and Drug Administration (FDA)
        Valproate. Major Drug Information Pages.
        http://www.fda.gov/cder/index.html
        (Accessed January 18, 2009)
        • Gutiérrez MJ
        • Villegas PH
        • Espinosa ZJ
        Therapeutic effectiveness of topiramate and magnesium valproate in children with Lennox-Gastaut syndrome.
        Rev Mex Pediatr. 2002; 69: 139-143
        • Ramos RR
        • López RM
        • Pérez ME
        • et al.
        Prophylactic treatment of migraine with magnesium valproate and its relationship with plasma levels.
        Rev Med Hosp General Mex. 2002; 65: 75-82
        • Rivera AC
        • Gutiérrez MJ
        • Venta SJ
        • et al.
        Response to treatment of partial seizures in children.
        Rev Esp Médico-Quirúgicas. 2003; 8: 12-16
        • Zaccara G
        • Messori A
        • Moroni F
        Clinical pharmacokinetics of valproic acid-1988.
        Clin Pharmacokinet. 1988; 15: 367-389
        • Pollack GM
        • McHugh WB
        • Gengo FM
        • et al.
        Accumulation and washout kinetics of valproic acid and its active metabolites.
        J Clin Pharmacol. 1986; 26: 668-676
        • Balbi A
        • Sottofattori E
        • Mazzei M
        • Sanniti WG
        Study of bioequivalence of magnesium and sodium valproates.
        J Pharm Biomed Anal. 1991; 9: 317-321
        • Amini H
        • Javan M
        • Ahmadiani A
        Development and validation of a sensitive assay of valproic acid in human plasma by high-performance liquid chromatography without prior derivatization.
        J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 830: 368-371
        • Cheng H
        • Liu Z
        • Blum W
        • et al.
        Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
        J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 850: 206-212
        • Ramakrishna NV
        • Vishwottam KN
        • Manoj S
        • et al.
        Liquid chromatography/electrospray ionization mass spectrometry method for the quantification of valproic acid in human plasma.
        Rapid Commun Mass Spectrom. 2005; 19: 1970-1978
        • NOM-177-SSA1-1998
        Tests and procedures to demonstrate interchangeability between pharmaceutical formulations [in Spanish]. Mexican Health Ministry, Mexico1998
        http://www.ssa.gob.mx/unidades/cdi/nom/177ssa18.html
        (or)
        http://www.feum.org/legisla/NOM-177PruebInter7may99.pdf
        (Accessed December 15, 2008)
        • US Dept of Health and Human Services, Food and Drug Administration (FDA)
        • Center for Drug Evaluation and Research (CDER)
        Guidance for industry: Statistical approaches to establishing bioequivalence.
        http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf
        (Accessed January 21, 2009)
        • Glazko AJ
        • Chang T
        • Daftsios AC
        • et al.
        Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt.
        Ther Drug Monit. 1983; 5: 409-417
        • Dutta S
        • Reed RC
        Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
        Epilepsy Res. 2007; 73: 275-283
        • Retzow A
        • Vens-Cappell B
        • Wangemann M
        Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation.
        Arzneimittelforschung. 1997; 47: 1347-1350
        • Chadwick DW
        Concentrationeffect relationship of valproic acid.
        Clin Pharmacokinet. 1985; 10: 155-163
        • Yan CS
        Appropriate dosage for maintaining effective serum levels at night after taking one dose of magnesium valproate with separate measurements of serum Mg++ concentration [in Chinese].
        Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991; 24: 18-20
        • Yan CS
        Appropriate dosage for maintaining effective serum levels at night after taking one dose of magnesium valproate with separate measurements of serum Mg++ concentration [in Chinese].
        Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991; 24: 61

      Article info

      Publication history

      Accepted: August 13, 2009

      Identification

      DOI: https://doi.org/10.1016/j.clinthera.2009.09.016

      Copyright

      © 2009 Excerpta Medica Inc. All rights reserved. Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX